1. Home
  2. PARK vs VTVT Comparison

PARK vs VTVT Comparison

Compare PARK & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Dental Partners Inc.

PARK

Park Dental Partners Inc.

N/A

Current Price

$21.35

Market Cap

94.5M

Sector

Health Care

ML Signal

N/A

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

N/A

Current Price

$21.00

Market Cap

104.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PARK
VTVT
Founded
1972
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.5M
104.9M
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
PARK
VTVT
Price
$21.35
$21.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$28.50
★ $56.00
AVG Volume (30 Days)
★ 45.2K
14.2K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ 0.16
N/A
Revenue
N/A
N/A
Revenue This Year
$5.58
N/A
Revenue Next Year
$15.70
N/A
P/E Ratio
$136.19
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$11.39
$20.56
52 Week High
$26.79
$44.00

Technical Indicators

Market Signals
Indicator
PARK
VTVT
Relative Strength Index (RSI) 59.42 22.64
Support Level $17.82 N/A
Resistance Level $26.79 $34.65
Average True Range (ATR) 1.46 1.40
MACD 0.18 -0.34
Stochastic Oscillator 99.25 4.59

Price Performance

Historical Comparison
PARK
VTVT

About PARK Park Dental Partners Inc.

Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: